RNA Therapeutics Market Size, Top Share

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global RNA Therapeutics Market Size Analysis

Global RNA Therapeutics Market Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. mRNA Therapeutics
  1. By Value
3. RNA interference (RNAi)
  1. By Value
4. Antisense oligonucleotides
  1. By Value
5. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Genetic Diseases
  1. By Value
5. Ophthalmology
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research Institutes
  1. By Value
4. Others
  1. By Value

North America Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. mRNA Therapeutics
  1. By Value
3. RNA interference (RNAi)
  1. By Value
4. Antisense oligonucleotides
  1. By Value
5. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Genetic Diseases
  1. By Value
5. Ophthalmology
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research Institutes
  1. By Value
4. Others
  1. By Value
U.S.
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. mRNA Therapeutics
    1. By Value
  3. RNA interference (RNAi)
    1. By Value
  4. Antisense oligonucleotides
    1. By Value
  5. Others
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Genetic Diseases
    1. By Value
  5. Ophthalmology
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research Institutes
    1. By Value
  4. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. mRNA Therapeutics
  1. By Value
3. RNA interference (RNAi)
  1. By Value
4. Antisense oligonucleotides
  1. By Value
5. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Genetic Diseases
  1. By Value
5. Ophthalmology
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research Institutes
  1. By Value
4. Others
  1. By Value
U.K.
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. mRNA Therapeutics
    1. By Value
  3. RNA interference (RNAi)
    1. By Value
  4. Antisense oligonucleotides
    1. By Value
  5. Others
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Genetic Diseases
    1. By Value
  5. Ophthalmology
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research Institutes
    1. By Value
  4. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. mRNA Therapeutics
  1. By Value
3. RNA interference (RNAi)
  1. By Value
4. Antisense oligonucleotides
  1. By Value
5. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Genetic Diseases
  1. By Value
5. Ophthalmology
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research Institutes
  1. By Value
4. Others
  1. By Value
China
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. mRNA Therapeutics
    1. By Value
  3. RNA interference (RNAi)
    1. By Value
  4. Antisense oligonucleotides
    1. By Value
  5. Others
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Genetic Diseases
    1. By Value
  5. Ophthalmology
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research Institutes
    1. By Value
  4. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. mRNA Therapeutics
  1. By Value
3. RNA interference (RNAi)
  1. By Value
4. Antisense oligonucleotides
  1. By Value
5. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Genetic Diseases
  1. By Value
5. Ophthalmology
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research Institutes
  1. By Value
4. Others
  1. By Value
UAE
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. mRNA Therapeutics
    1. By Value
  3. RNA interference (RNAi)
    1. By Value
  4. Antisense oligonucleotides
    1. By Value
  5. Others
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Genetic Diseases
    1. By Value
  5. Ophthalmology
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research Institutes
    1. By Value
  4. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Therapy Type
1. Introduction
  1. Therapy Type By Value
2. mRNA Therapeutics
  1. By Value
3. RNA interference (RNAi)
  1. By Value
4. Antisense oligonucleotides
  1. By Value
5. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Genetic Diseases
  1. By Value
5. Ophthalmology
  1. By Value
6. Cardiovascular Diseases
  1. By Value
7. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research Institutes
  1. By Value
4. Others
  1. By Value
Brazil
1. By Therapy Type
  1. Introduction
    1. Therapy Type By Value
  2. mRNA Therapeutics
    1. By Value
  3. RNA interference (RNAi)
    1. By Value
  4. Antisense oligonucleotides
    1. By Value
  5. Others
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Genetic Diseases
    1. By Value
  5. Ophthalmology
    1. By Value
  6. Cardiovascular Diseases
    1. By Value
  7. Others
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research Institutes
    1. By Value
  4. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

RNA Therapeutics Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Moderna, Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Pfizer Inc.
Alnylam Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Novartis AG
Sanofi
CureVac N.V.
Orna Therapeutics
Arrowhead Pharmaceuticals, Inc.
Suzhou Abogen Biosciences
CSPC Pharmaceutical
Dicerna Pharmaceuticals
Geron
Others

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment